The regulatory green light stems from longitudinal exposure-response modeling and findings from a Phase 3 trial extension. By shifting to an every-eight-week injection cycle, Eli Lilly aims to minimize the daily burden of the condition, which Adrienne Brown, executive vice president of Lilly Immunology, described as a move to help patients live with fewer interruptions from flares.

Eli Lilly retains exclusive rights to develop and market the drug globally, excluding Europe. In the European market, those rights are held by Almirall, which manages the treatment for dermatology indications. This approval marks a strategic expansion for the company, positioning the drug as a more flexible option for those managing chronic skin inflammation.